Table of Content

1.Product Overview
1.1.Market Definition
1.2.Scope of the Market
1.2.1.Markets Covered
1.2.2.Years Considered for Study
1.2.3.Key Market Segmentations
2.Research Methodology
2.1.Objective of the Study
2.2.Baseline Methodology
2.3.Key Industry Partners
2.4.Major Association and Secondary Sources
2.5.Forecasting Methodology
2.6.Data Triangulation Validation
2.7.Assumptions and Limitations
3.Executive Summary
3.1.Overview of the Market
3.2.Overview of Key Market Segmentations
3.3.Overview of Key Market Players
3.4.Overview of Key Regions/Countries
3.5.Overview of Market Drivers, Challenges, Trends
4.Voice of Customer
5.GlobalMacular Degeneration Treatment MarketOutlook
5.1.Market Size Forecast
5.1.1.By Value
5.2.Market Share Forecast
5.2.1.By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration)
5.2.2.By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD)
5.2.3.By Treatment Type (Drug,Devices,Surgery)
5.2.4.By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other)
5.2.5.By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
5.2.6.By Company (2023)
5.3.Market Map
5.3.1 By Type
5.3.2 By Stage of Disease
5.3.3 By Treatment Type
5.3.4 By Sales Channel
5.3.5 By Region
6.North America Macular Degeneration Treatment Market Outlook
6.1.Market Size Forecast
6.1.1.By Value
6.2.Market Share Forecast
6.2.1.By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration)
6.2.2.By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD)
6.2.3.By Treatment Type (Drug,Devices,Surgery)
6.2.4.By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other)
6.2.5.By Country
6.3.North America: Country Analysis
6.3.1.United States Macular Degeneration Treatment Market Outlook
6.3.1.1.Market Size Forecast
6.3.1.1.1.By Value
6.3.1.2.Market Share Forecast
6.3.1.2.1.By Type
6.3.1.2.2.By Stage of Disease
6.3.1.2.3.By Treatment Type
6.3.1.2.4.By Sales Channel
6.3.2.Canada Macular Degeneration Treatment Market Outlook
6.3.2.1.Market Size Forecast
6.3.2.1.1.By Value
6.3.2.2.Market Share Forecast
6.3.2.2.1.By Type
6.3.2.2.2.By Stage of Disease
6.3.2.2.3.By Treatment Type
6.3.2.2.4.By Sales Channel
6.3.3.Mexico Macular Degeneration Treatment Market Outlook
6.3.3.1.Market Size Forecast
6.3.3.1.1.By Value
6.3.3.2.Market Share Forecast
6.3.3.2.1.By Type
6.3.3.2.2.By Stage of Disease
6.3.3.2.3.By Treatment Type
6.3.3.2.4.By Sales Channel
7.Europe Macular Degeneration Treatment Market Outlook
7.1.Market Size Forecast
7.1.1.By Value
7.2.Market Share Forecast
7.2.1.By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration)
7.2.2.By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD)
7.2.3.By Treatment Type (Drug,Devices,Surgery)
7.2.4.By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other)
7.2.5.By Country
7.3.Europe: Country Analysis
7.3.1.France Macular Degeneration Treatment Market Outlook
7.3.1.1.Market Size Forecast
7.3.1.1.1.By Value
7.3.1.2.Market Share Forecast
7.3.1.2.1.By Type
7.3.1.2.2.By Stage of Disease
7.3.1.2.3.By Treatment Type
7.3.1.2.4.By Sales Channel
7.3.2.Germany Macular Degeneration Treatment Market Outlook
7.3.2.1.Market Size Forecast
7.3.2.1.1.By Value
7.3.2.2.Market Share Forecast
7.3.2.2.1.By Type
7.3.2.2.2.By Stage of Disease
7.3.2.2.3.By Treatment Type
7.3.2.2.4.By Sales Channel
7.3.3.United Kingdom Macular Degeneration Treatment Market Outlook
7.3.3.1.Market Size Forecast
7.3.3.1.1.By Value
7.3.3.2.Market Share Forecast
7.3.3.2.1.By Type
7.3.3.2.2.By Stage of Disease
7.3.3.2.3.By Treatment Type
7.3.3.2.4.By Sales Channel
7.3.4.Italy Macular Degeneration Treatment Market Outlook
7.3.4.1.Market Size Forecast
7.3.4.1.1.By Value
7.3.4.2.Market Share Forecast
7.3.4.2.1.By Type
7.3.4.2.2.By Stage of Disease
7.3.4.2.3.By Treatment Type
7.3.4.2.4.By Sales Channel
7.3.5.Spain Macular Degeneration Treatment Market Outlook
7.3.5.1.Market Size Forecast
7.3.5.1.1.By Value
7.3.5.2.Market Share Forecast
7.3.5.2.1.By Type
7.3.5.2.2.By Stage of Disease
7.3.5.2.3.By Treatment Type
7.3.5.2.4.By Sales Channel
8.Asia-Pacific Macular Degeneration Treatment Market Outlook
8.1.Market Size Forecast
8.1.1.By Value
8.2.Market Share Forecast
8.2.1.By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration)
8.2.2.By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD)
8.2.3.By Treatment Type (Drug,Devices,Surgery)
8.2.4.By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other)
8.2.5.By Country
8.3.Asia-Pacific: Country Analysis
8.3.1.China Macular Degeneration Treatment Market Outlook
8.3.1.1.Market Size Forecast
8.3.1.1.1.By Value
8.3.1.2.Market Share Forecast
8.3.1.2.1.By Type
8.3.1.2.2.By Stage of Disease
8.3.1.2.3.By Treatment Type
8.3.1.2.4.By Sales Channel
8.3.2.India Macular Degeneration Treatment Market Outlook
8.3.2.1.Market Size Forecast
8.3.2.1.1.By Value
8.3.2.2.Market Share Forecast
8.3.2.2.1.By Type
8.3.2.2.2.By Stage of Disease
8.3.2.2.3.By Treatment Type
8.3.2.2.4.By Sales Channel
8.3.3.Japan Macular Degeneration Treatment Market Outlook
8.3.3.1.Market Size Forecast
8.3.3.1.1.By Value
8.3.3.2.Market Share Forecast
8.3.3.2.1.By Type
8.3.3.2.2.By Stage of Disease
8.3.3.2.3.By Treatment Type
8.3.3.2.4.By Sales Channel
8.3.4.South Korea Macular Degeneration Treatment Market Outlook
8.3.4.1.Market Size Forecast
8.3.4.1.1.By Value
8.3.4.2.Market Share Forecast
8.3.4.2.1.By Type
8.3.4.2.2.By Stage of Disease
8.3.4.2.3.By Treatment Type
8.3.4.2.4.By Sales Channel
8.3.5.Australia Macular Degeneration Treatment Market Outlook
8.3.5.1.Market Size Forecast
8.3.5.1.1.By Value
8.3.5.2.Market Share Forecast
8.3.5.2.1.By Type
8.3.5.2.2.By Stage of Disease
8.3.5.2.3.By Treatment Type
8.3.5.2.4.By Sales Channel
9.South America Macular Degeneration Treatment Market Outlook
9.1.Market Size Forecast
9.1.1.By Value
9.2.Market Share Forecast
9.2.1.By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration)
9.2.2.By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD)
9.2.3.By Treatment Type (Drug,Devices,Surgery)
9.2.4.By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other)
9.2.5.By Country
9.3.South America: Country Analysis
9.3.1.Brazil Macular Degeneration Treatment Market Outlook
9.3.1.1.Market Size Forecast
9.3.1.1.1.By Value
9.3.1.2.Market Share Forecast
9.3.1.2.1.By Type
9.3.1.2.2.By Stage of Disease
9.3.1.2.3.By Treatment Type
9.3.1.2.4.By Sales Channel
9.3.2.Argentina Macular Degeneration Treatment Market Outlook
9.3.2.1.Market Size Forecast
9.3.2.1.1.By Value
9.3.2.2.Market Share Forecast
9.3.2.2.1.By Type
9.3.2.2.2.By Stage of Disease
9.3.2.2.3.By Treatment Type
9.3.2.2.4.By Sales Channel
9.3.3.Colombia Macular Degeneration Treatment Market Outlook
9.3.3.1.Market Size Forecast
9.3.3.1.1.By Value
9.3.3.2.Market Share Forecast
9.3.3.2.1.By Type
9.3.3.2.2.By Stage of Disease
9.3.3.2.3.By Treatment Type
9.3.3.2.4.By Sales Channel
10.Middle East and Africa Macular Degeneration Treatment Market Outlook
10.1.Market Size Forecast
10.1.1.By Value
10.2.Market Share Forecast
10.2.1.By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration)
10.2.2.By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD)
10.2.3.By Treatment Type (Drug,Devices,Surgery)
10.2.4.By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other)
10.2.5.By Country
10.3.MEA: Country Analysis
10.3.1.South Africa Macular Degeneration Treatment Market Outlook
10.3.1.1.Market Size Forecast
10.3.1.1.1.By Value
10.3.1.2.Market Share Forecast
10.3.1.2.1.By Type
10.3.1.2.2.By Stage of Disease
10.3.1.2.3.By Treatment Type
10.3.1.2.4.By Sales Channel
10.3.2.Saudi Arabia Macular Degeneration Treatment Market Outlook
10.3.2.1.Market Size Forecast
10.3.2.1.1.By Value
10.3.2.2.Market Share Forecast
10.3.2.2.1.By Type
10.3.2.2.2.By Stage of Disease
10.3.2.2.3.By Treatment Type
10.3.2.2.4.By Sales Channel
10.3.3.UAE Macular Degeneration Treatment Market Outlook
10.3.3.1.Market Size Forecast
10.3.3.1.1.By Value
10.3.3.2.Market Share Forecast
10.3.3.2.1.By Type
10.3.3.2.2.By Stage of Disease
10.3.3.2.3.By Treatment Type
10.3.3.2.4.By Sales Channel
11.Market Dynamics
11.1.Drivers
11.2.Challenges
12.Market Trends Developments
12.1.Recent Development
12.2.Mergers Acquisitions
12.3.Product Launches
13.Global Macular Degeneration Treatment Market: SWOT Analysis
14.Porter’s Five Forces Analysis
14.1.Competition in the Industry
14.2.Potential of New Entrants
14.3.Power of Suppliers
14.4.Power of Customers
14.5.Threat of Substitute Products
15.Competitive Landscape
15.1.F Hoffmann-La Roche Ltd
15.1.1.Business Overview
15.1.2.Product Offerings
15.1.3.Recent Developments
15.1.4.Financials (As Reported)
15.1.5.Key Personnel
15.1.6.SWOT Analysis
15.2.Novartis AG
15.3.Pfizer Inc.
15.4.PanOptica Inc.
15.5.Bausch Health Companies Inc.
15.6.Regeneron Pharmaceuticals Inc.
15.7.Aerie Pharmaceutical Inc.
15.8.REGENXBIO Inc.
15.9.Bayer AG
15.10.Lineage Cell Therapeutics Inc.
16.Strategic Recommendations
17.About Us Disclaimer